United Health Products, Inc.
UEECDrugs in Pipeline
11
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Oral Treprostinil
Pulmonary Arterial Hypertension
Oral treprostinil (UT-15C) sustained release tablets
Pulmonary Hypertension
Inhaled Treprostinil
Pulmonary Hypertension
Ralinepag
PAH
UBT251
Obesity &Amp; Overweight
UI-102
Advanced Cancer
UB-421(25 mg/kg) Q2W
HIV-1 Infection
0.5% Ivermectin lotion
Pediculosis Capitis
treprostinil diethanolamine
Systemic Sclerosis
UB-421
HIV-1 Infection
UT-15C SR
Pulmonary Arterial Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral Treprostinil | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Oral treprostinil (UT-15C) sustained release tablets | Phase 3 | Pulmonary Hypertension | - | - |
Inhaled Treprostinil | Phase 3 | Pulmonary Hypertension | - | - |
Ralinepag | Phase 3 | PAH | - | - |
UBT251 | Phase 2 | Obesity &Amp; Overweight | - | - |
UI-102 | Phase 2 | Advanced Cancer | - | - |
UB-421(25 mg/kg) Q2W | Phase 2 | HIV-1 Infection | - | - |
0.5% Ivermectin lotion | Phase 2 | Pediculosis Capitis | - | - |
treprostinil diethanolamine | Phase 2 | Systemic Sclerosis | - | - |
UB-421 | Phase 2 | HIV-1 Infection | - | - |
UT-15C SR | Phase 2 | Pulmonary Arterial Hypertension | - | - |